×
About 173 results

ALLMedicine™ Pediatric Neuroblastoma Center

Research & Reviews  54 results

Lipid emulsion-induced hypertension post resection of pediatric neuroblastoma: a case r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036777
BMC Pediatrics; Yuan L, Li T et. al.

Apr 27th, 2022 - Parenteral Nutrition (PN) is preferred when patient is unable to eat. Most clinically widely used lipid emulsion is now attracting more attention in its stability and adverse reactions. We report here the first case of lipid emulsions caused hyper...

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02924324

Apr 26th, 2022 - The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The...

CT-based morphologic and radiomics features for the classification of MYCN gene amplifi...
https://doi.org/10.1007/s00381-022-05534-3 10.1148/rg.2018170132 10.3322/caac.21654 10.1002/pbc.27556 10.1002/pbc.27363 10.1200/JCO.2008.16.6785 10.1200/jco.2011.29.18_suppl.2 10.1016/S1470-2045(05)70291-6 10.1016/j.jpedsurg.2018.12.023 10.1016/j.jpedsurg.2018.04.012 10.1016/j.jpedsurg.2012.03.040 10.1002/pbc.28153 10.1158/0008-5472.CAN-17-0339 10.1148/radiol.2015151169 10.7150/thno.30309 10.1007/s00261-019-02028-w 10.1056/NEJMoa1113205 10.1038/sj.bjc.6605014 10.18637/jss.v028.i05 10.1200/JCO.2008.16.6876 10.1002/pbc.26605 10.1148/radiol.11101352 10.1016/j.mri.2012.05.001 10.1148/radiol.2020191145 10.1093/bioinformatics/btt383 10.1111/rssb.12377 10.1007/s12021-010-9074-x 10.21105/joss.00786 10.1016/j.ijmedinf.2020.104313 10.3389/fonc.2021.687884 10.1007/s00330-020-07246-1 10.1002/pbc.29110 10.3389/fonc.2020.624079 10.1016/j.ijrobp.2018.05.053 10.1080/0284186X.2018.1445283 10.1186/s40644-019-0276-7 10.1038/s41598-018-36938-4 10.1038/s41416-020-0740-y 10.1016/j.compbiomed.2021.104752 10.1007/s00234-020-02403-1 10.1371/journal.pone.0217785 10.1016/j.ejca.2020.04.007 10.1002/pbc.28794 10.1038/nature12477
Child's Nervous System : ChNS : Official Journal of the I... Tan E, Merchant K et. al.

Apr 24th, 2022 - MYCN onco-gene amplification in neuroblastoma confers patients to the high-risk disease category for which prognosis is poor and more aggressive multimodal treatment is indicated. This retrospective study leverages machine learning techniques to d...

A hypothalamic pathway for Augmentor α-controlled body weight regulation.
https://doi.org/10.1073/pnas.2200476119
Proceedings of the National Academy of Sciences of the Un... Ahmed M, Kaur N et. al.

Apr 13th, 2022 - SignificanceThe receptor tyrosine kinase Alk was originally discovered as an oncogenic fusion protein generated in anaplastic large cell lymphoma. A variety of oncogenic Alk fusion proteins were subsequently identified as key drivers of subsets of...

see more →

Clinicaltrials.gov  3 results

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02924324

Apr 26th, 2022 - The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The...

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
https://clinicaltrials.gov/ct2/show/NCT02332889

May 4th, 2018 - One of the challenges of the practical application of immunotherapy for brain tumors is the lack of expression of tumor antigens as well as the down-regulation of Major Histocompatibility Complex (MHC Class I and II ) molecules, which are needed f...

Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT02615106

Jun 14th, 2016 - Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. So investigators design Radiotherapy plus Endosta...

see more →

News  12 results

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma
https://www.onclive.com/view/activating-the-immune-system-could-be-key-to-treating-pediatric-neuroblastoma

Mar 10th, 2022 - Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma. Wayne Furman, MD, hopes that the humanized anti-disialoganglioside (anti-GD2) monoclonal antibody hu14.18K322A provides a breakthrough for children wi...

Rare Cancers Report: Pediatric Neuroblastoma
https://www.onclive.com/view/rare-cancers-report-pediatric-neuroblastoma

Feb 3rd, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and p...

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment
https://www.onclive.com/view/yale-cancer-center-researchers-show-receptor-structure-reveals-new-targets-for-cancer-treatment

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...

Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma
https://www.medpagetoday.com/hematologyoncology/othercancers/96035

Dec 6th, 2021 - Adding a novel anti-GD2 antibody (hu14.18K322A) to induction chemotherapy for children with newly diagnosed high-risk neuroblastoma yielded impressive survival outcomes and improved early responses versus historical benchmarks, investigators repor...

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off
https://www.onclive.com/view/persistent-development-of-wee1-pathway-inhibitors-begins-to-pay-off

Aug 25th, 2021 - WEE1 is a key regulator of the cell cycle that has been a target of cancer drug discovery efforts for more than a decade. The lead novel candidate, the WEE1 inhibitor adavosertib (AZD1775), has been tested in more than 50 completed or ongoing clin...

see more →